Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 85
- 试验地点
- 1
- 主要终点
- Number of appropriate weekly dose
研究概览
简要总结
The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.
详细描述
The study mainly focused for the following objectives:
To determine the effect of semaglutide on ovulation and menstrual regularity. To determine the effect of semaglutide on androgen levels, namely testosterone, sex hormone binding globulin, and changes in hirsutism.
To determine changes in weight, body mass index (BMI), and Glycated Hemoglobin( HbA1c) with semaglutide therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age 18-45
- •Body mass index(BMI) > 30
- •Diagnosis of PCOS
- •Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone
排除标准
- •Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
- •Letrozole, clomiphene citrate, FSH therapy
- •Androgen receptor blockers
- •5α reductase inhibitors
- •Hysterectomy
- •Endometrial ablation
研究组 & 干预措施
Protocol group
PCOS women in the age 18 to 45 years
干预措施: Semaglutide (Drug)
结局指标
主要结局
Number of appropriate weekly dose
时间窗: 4 weeks
To access the compliances of the therapy
Number of days on therapy
时间窗: 4 weeks
To access the persistence on Semaglutide
次要结局
- measure the Weight in kilograms(4 weeks)
- Numbers of days with exercise changes(4 weeks)